| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
Susan M Stalnecker is Director at BVS, with reported holdings spanning 2 companies. Susan M Stalnecker's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $4.3M at current prices.
Susan M Stalnecker's largest disclosed position is in LDOS as Director, worth about $2.8M. The LDOS filings lean toward selling, a net 3,014 shares.
Susan M Stalnecker has 19 Form 4 filings on record from May 2019 to June 2026, across 2 companies: Director at Bioventus (BVS), 2021–2026; Director at Leidos (LDOS), 2019–2025.
The 35 reported transactions were 13 option exercises, 12 option or other derivative awards, 6 stock awards and 3 tax withholdings, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 1 sale worth about $428K.
The only open-market sale was 3,014 shares of LDOS at an average $141.97 on May 2, 2024, about $428K. Twelve months later LDOS was up 4%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 2, 2024 | LDOS Leidos Holdings, Inc. | Director | Sale+OE | 3,014 | $141.97 | $427,909.03 | -17.0% | +1.2% | +4.3% |